AI assistant
Sending…
Evogene Ltd. — Proxy Solicitation & Information Statement 2025
Jul 17, 2025
6785_rns_2025-07-17_7c4d65bf-aa51-4ba6-b68f-297c70c3a437.htm
Proxy Solicitation & Information Statement
Open in viewerOpens in your device viewer
_________ false
| ����� ��"� | 2 381 |
| EVOGENE LTD | |
| Corporation no: 512838723 | 14299 |
| - - - | |
| Israel Securities Authority | Tel Aviv Stock Exchange | C003 ( Public ) | Reported via MAGNA: | 17/07/2025 | ||||||
| www.isa.gov.il | www.tase.co.il | Reference: | 2025-02-053352 | Time of broadcast: 17:44 17:44 |
The corporation scheduled the publication of the report to 17/07/2025 23:00Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
| Attached hereto is a report on | Supplemental Submission of Proxy Card for Annual General Meeting of Shareholders |
6K_EVGN_proxy_card_isa.pdf
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): | |
| 2025-02-043133 | |
| - - - | |
| Stock Exchange/Market: -1 | Date of revision of form structure: 06/08/2024 |
| Address: Gad Feinstein St 13, P.O.B 2100 , Rehovot 76121 , Tel: 08-9311900 , Fax: 08-9466724 | |
| E-mail address: [email protected] Company site: www.evogene.com | |
| Previous names of reporting entity: | |
| Name of the Signatory: Deutsch Nitsan Position of Signatory in the reporting corporation: Chief Legal Officer & Secretary Name of Employer Company: | |
| Address: Gad Feinstein 13 , Rehovot 7638517 Telephone: 08-9311900 Facsimile: 08-9466724 E-mail: [email protected] 1 | |
More from Evogene Ltd.
Report Publication Announcement
2026
May 18
Regulatory Filings
2026
May 18
Foreign Filer Report
2026
May 18
Report Publication Announcement
2026
May 12
Regulatory Filings
2026
May 12
Regulatory Filings
2026
May 7
Regulatory Filings
2026
May 7
Director's Dealing
2026
Apr 9
Director's Dealing
2026
Apr 9
Regulatory Filings
2026
Apr 2